-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TGJA364CHfN5PFSEgAdj+L8F8DPI9ZH4T64YqwSClVsvVCzQqmYANUGbWRBR8DxB CyRZYdVxFvmFvQomKzwaPA== 0001305239-06-000002.txt : 20061025 0001305239-06-000002.hdr.sgml : 20061025 20061025170956 ACCESSION NUMBER: 0001305239-06-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061023 FILED AS OF DATE: 20061025 DATE AS OF CHANGE: 20061025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trubion Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001298521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 2401 14TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2068380500 MAIL ADDRESS: STREET 1: 2401 14TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Venrock Partners, L.P. CENTRAL INDEX KEY: 0001305239 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33054 FILM NUMBER: 061163513 BUSINESS ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA, ROOM 5508 CITY: NEW YORK STATE: NY ZIP: 10112 BUSINESS PHONE: 212-649-5600 MAIL ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA, ROOM 5508 CITY: NEW YORK STATE: NY ZIP: 10112 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2006-10-23 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001305239 Venrock Partners, L.P. 30 ROCKEFELLER PLAZA, ROOM 5508 NEW YORK NY 10112 0 0 1 0 Common Stock 2006-10-23 4 C 0 302527 A 302527 D Common Stock 2006-10-23 4 P 0 5840 13.00 A 308367 D Series B Preferred Stock 2006-10-23 4 C 0 302527 D Common Stock 302527 0 D Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock was automatically converted into Common Stock on a 1-for-1 basis. Shares of Preferred Stock were convertible into Common Stock at any time and had no expiration date. All outstanding shares of Preferred Stock were automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Not applicable. Anders D. Hove, Member of Venrock Partners Management, LLC, the General Partner of Venrock Partners, L.P. 2006-10-25 -----END PRIVACY-ENHANCED MESSAGE-----